tetano
Editor, Senior Moderator
Front Immunol
. 2024 Jul 5:15:1428645.
doi: 10.3389/fimmu.2024.1428645. eCollection 2024. Autoantibodies in COVID-19 survivors with post-COVID symptoms: a systematic review
Kin Israel Notarte[SUP] 1 [/SUP], Timothy Hudson David Culasino Carandang[SUP] 2 [/SUP], Jacqueline Veronica Velasco[SUP] 3 [/SUP], Adriel Pastrana[SUP] 4 [/SUP], Abbygail Therese Ver[SUP] 4 [/SUP], Gerald Neil Manalo[SUP] 4 [/SUP], Jeremy Ace Ng[SUP] 5 [/SUP], Steven Grecia[SUP] 4 [/SUP], Giuseppe Lippi[SUP] 6 [/SUP], Brandon Michael Henry[SUP] 7 [/SUP], César Fernández-de-Las-Peñas[SUP] 8 [/SUP]
Affiliations
Objective: The long-lasting persistence of autoantibodies stands as one of the hypotheses explaining the multisystemic manifestations seen in individuals with post-COVID-19 condition. The current review offers restricted insights into the persistence of autoantibodies in plasma/serum in people with post-COVID symptoms.
Methods: PubMed/MEDLINE, CINAHL, EMBASE, and Web of Science databases, as well as on medRxiv and bioRxiv preprint servers were searched up to January 5[SUP]th[/SUP], 2024. Papers investigating the presence of autoantibodies in plasma/serum samples in people with post-COVID symptoms were included. The Newcastle-Ottawa Scale (NOS) was used to assess methodological quality.
Results: From 162 identified records, five articles met all inclusion criteria; four studies included infected controls with no post-COVID symptoms whereas all five studies included non-infected controls (410 COVID-19 survivors with post-COVID symptoms, 223 COVID-19 survivors with no post-COVID symptoms as controls and 266 non-infected healthy controls). Four studies concluded that the presence of autoantibodies had a potential (but small) role in post-COVID-19 condition whereas one study concluded that autoantibodies were not associated. Quality assessment showed all studies had high methodological quality.
Conclusion: Although evidence suggests that persistent autoantibodies can be associated with post-COVID symptoms, the clinical relevance of their presence seems modest at this stage. Current results highlight further research to clarify the role of autoantibodies in the development of post-COVID symptoms, guiding the development of tailored diagnostic and treatment approaches to enhance patient outcomes.
Systematic review registration: https://osf.io/vqz28.
Keywords: PASC; SARS-CoV-2 infection (COVID-19); autoantibodies; long COVID; post-COVID-19.
. 2024 Jul 5:15:1428645.
doi: 10.3389/fimmu.2024.1428645. eCollection 2024. Autoantibodies in COVID-19 survivors with post-COVID symptoms: a systematic review
Kin Israel Notarte[SUP] 1 [/SUP], Timothy Hudson David Culasino Carandang[SUP] 2 [/SUP], Jacqueline Veronica Velasco[SUP] 3 [/SUP], Adriel Pastrana[SUP] 4 [/SUP], Abbygail Therese Ver[SUP] 4 [/SUP], Gerald Neil Manalo[SUP] 4 [/SUP], Jeremy Ace Ng[SUP] 5 [/SUP], Steven Grecia[SUP] 4 [/SUP], Giuseppe Lippi[SUP] 6 [/SUP], Brandon Michael Henry[SUP] 7 [/SUP], César Fernández-de-Las-Peñas[SUP] 8 [/SUP]
Affiliations
- PMID: 39035011
- PMCID: PMC11257835
- DOI: 10.3389/fimmu.2024.1428645
Objective: The long-lasting persistence of autoantibodies stands as one of the hypotheses explaining the multisystemic manifestations seen in individuals with post-COVID-19 condition. The current review offers restricted insights into the persistence of autoantibodies in plasma/serum in people with post-COVID symptoms.
Methods: PubMed/MEDLINE, CINAHL, EMBASE, and Web of Science databases, as well as on medRxiv and bioRxiv preprint servers were searched up to January 5[SUP]th[/SUP], 2024. Papers investigating the presence of autoantibodies in plasma/serum samples in people with post-COVID symptoms were included. The Newcastle-Ottawa Scale (NOS) was used to assess methodological quality.
Results: From 162 identified records, five articles met all inclusion criteria; four studies included infected controls with no post-COVID symptoms whereas all five studies included non-infected controls (410 COVID-19 survivors with post-COVID symptoms, 223 COVID-19 survivors with no post-COVID symptoms as controls and 266 non-infected healthy controls). Four studies concluded that the presence of autoantibodies had a potential (but small) role in post-COVID-19 condition whereas one study concluded that autoantibodies were not associated. Quality assessment showed all studies had high methodological quality.
Conclusion: Although evidence suggests that persistent autoantibodies can be associated with post-COVID symptoms, the clinical relevance of their presence seems modest at this stage. Current results highlight further research to clarify the role of autoantibodies in the development of post-COVID symptoms, guiding the development of tailored diagnostic and treatment approaches to enhance patient outcomes.
Systematic review registration: https://osf.io/vqz28.
Keywords: PASC; SARS-CoV-2 infection (COVID-19); autoantibodies; long COVID; post-COVID-19.